1. Van Hemelrijck M, Garmo H, Lindhagen L, Bratt O, Stattin P, Adolfsson J. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer, Eur Urol. Nov 2 2016. Sammanfattning
  2. Häggström C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, Gudbjörnsdottir S, Garmo H, Stattin P. Prospective study of Type 2 Diabetes Mellitus, anti-diabetic drugs, and risk of prostate cancer, Int J Cancer. Oct 22 2016. Sammanfattning
  3. Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden, JAMA Oncol. Oct 20 2016. Sammanfattning
  4. Tomic K, Westerberg M, Robinson D, Garmo H, Stattin P. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden, Acta Oncol. Oct 17 2016. Sammanfattning
  5. Wilson KM, Markt SC, Fang F, Nordenvall C, Rider JR, Ye W, Adami HO, Stattin P, Nyrén O, Mucci LA. Snus use, smoking and survival among prostate cancer patients, Int J Cancer. Sep 1 2016. Sammanfattning
  6. Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M. Association between duration and type of Androgen Deprivation Therapy and risk of diabetes in men with prostate cancer, Int J Cancer. Aug 25 2016. Sammanfattning
  7. Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy, J Surg Oncol. Aug 11 2016. Sammanfattning
  8. Loeb S, Stattin P. Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma, Eur Urol. Jul 16 2016. Sammanfattning
  9. Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study, J Natl Cancer Inst. Jul 10 2016. Sammanfattning, Fulltext
  10. Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, Jonsson H, Bratt O. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study, Eur Urol. Jul 29 2016. Sammanfattning
  11. Thorstenson A, Garmo H, Adolfsson J, Bratt O. Cancer-specific mortality in men diagnosed with prostate cancer before age 50 years, a nationwide population-based study, J Urol. Jun 17 2016. Sammanfattning
  12. Fridriksson JÖ, Folkvaljon Y, Nilsson P, Robinson D, Franck-Lissbrant I, Ehdaie B, Eastham JA, Widmark A, Karlsson CT, Stattin P. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study, Scand J Urol. Jun 22:1-8 2016. Sammanfattning
  13. Bjartell A, Bottai M, Persson J, Bratt O, Damber JE, Stattin P, Akre O. Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort, Scand J Urol. May 18 2016. Sammanfattning
  14. Stattin P. Svenska kvalitetsregister slår hål på larmrapporter – Register med stora studiepopulationer ger liten risk för fynd baserade på slump eller förväxling, Läkartidningen Apr 20 2016. Sammanfattning, Artikel
  15. Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, Stattin P. Immediate versus delayed prostatectomy: Nationwide population-based study, Scand J Urol. Apr 12 2016. Sammanfattning
  16. Arthur R, Møller H, Garmo H, Holmberg L, Stattin P, Malmstrom H, Lambe M, Hammar N, Walldius G, Robinson D, Jungner I, Hemelrijck MV. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories, Cancer Med. Feb 29 2016. Sammanfattning
  17. Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy, Scand J Urol. Mar 3 2016. Sammanfattning
  18. Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012, BJU Int. Feb 25 2016. Sammanfattning
  19. Plym A, Voss M, Stattin P, Lambe M. Assessing Work Disability After Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.01.005: The Challenge of Assessing Work Disability, Eur Urol. Feb 9, 2016. Sammanfattning, Fulltext
  20. Loeb S, Lambe M, Stattin P. Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711, J Urol. Jan 16 2016. Sammanfattning
  21. Plym A, Chiesa F, Voss M, Holmberg L, Johansson E, Stattin P, Lambe M. Work Disability After Robot-assisted or Open Radical Prostatectomy: A Nationwide, Population-based Study, Eur Urol. Jan 15 2016 Sammanfattning, Fulltext
  22. Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment, Eur Urol. Dec 29 2015 Sammanfattning
  23. Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O. Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study, BJU Int. Jan 13 2016 Sammanfattning